No Data
Calculating The Fair Value Of Zhejiang Huakang Pharmaceutical Co., Ltd. (SHSE:605077)
Huakang Corporation (605077.SH): Fujian Yake's shareholding ratio has decreased to 5.00%.
Gelonghui, on November 25th, announced that Huakang Co., Ltd. (605077.SH) received a "Report on Simplified Changes in Equity" issued by Fujian Yake. Between October 16, 2024, and November 22, 2024, Fujian Yake reduced its shareholding in the company by 2,945,814 shares through centralized bidding. After this change in equity, Fujian Yake's shareholding decreased from 18,239,858 shares to 15,294,044 shares, and its shareholding ratio declined from 5.98% to 5.00%.
Zhejiang Huakang Pharmaceutical Co., Ltd. (SHSE:605077) Looks Inexpensive But Perhaps Not Attractive Enough
Huakang Co., Ltd. (605077.SH) is planning to purchase all or part of the equity of Yuxin Sorbitol. Stock and bond trading will be suspended from October 28th.
Huakang Co., Ltd. (605077.SH) announced that the company is planning to combine the issuance of shares with cash payments in a...
Huakang Stock Report for the Third Quarter of 2024
Announcement of Huakang Co., Ltd. on major operating data from January to September 2024